Friday, August 17, 2012

24 August 2012: Public finance of tuberculosis treatment in India: an extended cost-effectiveness analysis

Ramanan Laxminarayan
Princeton University

Cost-effectiveness evaluations of health interventions assess the cost
per unit of health gained from the intervention. A typical finding
would be that it costs about $1,000 to avert a death from tuberculosis
(TB) using modern drug treatments. A separate question, much less
frequently addressed, is the economic attractiveness of different
instruments for implementing an intervention in a population. Such
instruments can include mass campaigns or conditional cash transfers
to encourage treatment seeking, and partial to total public finance
for a specific intervention. Our purpose here is to develop methods
for the economic evaluation of alternative implementation instruments
through the example of universal public finance (UPF) as an
instrument. We label this approach, extended cost-effectiveness
analysis or ECEA, and illustrate our methods while taking the example
of TB treatment in India to assess three dimensions of consequences:
the level and distribution (across wealth quintiles) of the burden of
disease averted, of the net consequences of taxation and private
expenditures averted, and of the value of insurance provided. Using
plausible values for key parameters we find health gains to be
substantial and concentrated among the poor; the insurance value and
the net consequences of taxation and private expenditures averted to
vary with key assumptions.

Date: August 24, 2012
Time: 11:30 A.M.

Seminar Room 2
Indian Statistical Institute Delhi Centre,
7, S. J. S. Sansanwal Marg,
New Delhi-110016 (INDIA)


View Larger Map

No comments:

Post a Comment